SELLAS Life Sciences Group, Inc.
13.95USD
-0.0100 (-0.07%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -11 | -9 | -8 | -7 | -7 | -6 | -7 | -7 |
| Net Income | -10 | -8 | -8 | -7 | -7 | -6 | -7 | -7 |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.08 | $-0.10 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)